Cancer of the oesophagus and lymph nodes management in the neoadjuvant or definitive radiochemotherapy setting |
| |
Authors: | V. Bourbonné O. Pradier U. Schick S. Servagi-Vernat |
| |
Affiliation: | 1. Radiation Oncology Department, CHU de Brest, 29200 Brest, France;2. Radiation Oncology Department, CHU de Reims, 51100 Reims, France |
| |
Abstract: | Despite representing a 1% of diagnosed cancer cases in the USA and up to 5% in eastern Asia and Africa, oesophageal cancer still holds numerous questions concerning the best therapeutic management. For squamous cell carcinoma, while radiochemotherapy has proven itself to be the gold standard as part of the trimodality or alone as a definitive treatment, radiotherapy modalities are still debated especially regarding lymph node irradiation. Involved nodes irradiation was developed with the aim of maintaining clinical outcomes and enhancing quality of life but lacks grade 1 evidence. In this article, we aim to summarize the state of art regarding lymph node irradiation, discuss the impact of target definition, delivery techniques, concomitant treatment and the perspectives. Being highly connected to the lymph vessels, lymphatic metastases are frequent and can locate from the neck to the coeliac area with each node having a different prognostic significance. Regarding the comparison between elective nodal irradiation and involved nodes irradiation, evidence-based medicine mostly relies on retrospective studies. Pooled, it suggests similar clinical outcomes with lower acute toxicities in favour of involved nodes irradiation. However, delivery techniques, doses and concomitant treatment were not consensual. Studies are ongoing evaluating the impact of radiation delivery techniques and the choice of concomitant treatment, i.e. immunotherapy. Modern techniques of imaging, radiation therapy progressing each day and alternative treatment modalities being tested, the need of randomized controlled trials has never been so high. Elective nodal irradiation should remain the standard of care while phase 3 trials explore the safety of involved nodal irradiation. |
| |
Keywords: | Corresponding author. Cancer Oesophagus Lymph node Prophylactic radiotherapy Involved radiotherapy Target Volume Cancer ?sophage Irradiation Ganglionnaire prophylactique Irradiation ganglionnaire sélective Volume cible |
本文献已被 ScienceDirect 等数据库收录! |
|